Información de la revista
Vol. 4. Núm. S1.
Monográfico: Enfermedades sistémicas autoinmunitarias
Páginas 31-34 (Marzo 2008)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 4. Núm. S1.
Monográfico: Enfermedades sistémicas autoinmunitarias
Páginas 31-34 (Marzo 2008)
Enfermedades sistémicas autoinmunitarias
Acceso a texto completo
Resultados de los tratamientos biológicos en las enfermedades autoinmunitarias
Results of Biological Treatments in Autoimmune Diseases
Visitas
12061
Paloma Vela Casasempere
Autor para correspondencia
palomavela@coma.es
vela_pal@gva.es

Correspondencia: Dra. P. Vela Casasempere. Hospital General Universitario de Alicante. Maestro Alonso, 109. Alicante. España.
Hospital General Universitario de Alicante. Alicante. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

El uso de los tratamientos biológicos ha revolucionado en los últimos años el manejo de numerosos procesos autoinmunitarios. Ello ha llevado a numerosos investigadores y clínicos a intentar aplicar estas terapias en otras enfermedades (lupus, síndrome de Sjögren, vasculitis, etc.). Desde la introducción de los corticoides e inmunosupresores, las vasculitis pasaron de ser enfermedades mortales a tener tasas de remisión elevadas. Sin embargo, son tardías, no son permanentes y requieren el uso mantenido de fármacos. En este contexto, los nuevos fármacos biológicos han de superar el reto de inducir una remisión temprana y permanente que minimice el daño orgánico irreversible, reducir (o eliminar) la exposición a esteroides e inmunosupresores y mejorar la función del paciente. En este capítulo se revisan los datos que existen actualmente en la literatura respecto a la utilidad de los fármacos biológicos en las vasculitis sistémicas.

Palabras clave:
Agentes biológicos
Anti-TNFα
Rituximab
Interferón alfa
Vasculitis
Arteritis de células gigantes
Arteritis de Takayasu
Enfermedad de Behçet
Síndrome de Churg-Strauss
Granulomatosis de Wegener

The use of the biological therapies has revolutionized in the last years the handling of numerous autoimmune processes. It has taken to numerous physicians and investigators to try to apply these therapies in other diseases (lupus, Sjögren, vasculitis, etc). From the introduction of corticosteroids and immunosupressives, vasculitis were no more a mortal diseases, and it was possible to obtain high rates of remission. Nevertheless, they are delayed, they are not sustained, and require of the use of maintained drugs. Against this background, the new biological drugs have to surpass the challenge to induce an earlier and permanent remission that diminishes irreversible organ damage, to reduce (or to eliminate) the exposition to steroids and immunesupressives and to improve the patient function. This article reviews data present until now in literature with respect to the utility of biological drugs in systemic vasculitis.

Key words:
Biologic agents
Anti-TNFα
Rituximab
Interferon alpha
Vasculitis
Giant cell arteritis
Takayasu's arteritis
Behçet disease
Churg-Strauss syndrome
Wegener granulomatosis
El Texto completo está disponible en PDF
Bibliografía
[1.]
D. Jayne.
What place for the new biologics in the treatment of necrotising vasculitides.
Clin Exp Rheumatol, 24 (2006), pp. 1-5
[2.]
C.L. Koening, C.A. Langford.
Novel therapeutic strategies for large vessel vasculitis.
Rheum Dis Clin North Am, 32 (2006), pp. 173-186
[3.]
G.S. Hoffman, M.C. Cid, K.E. Rendt-Zagar, et al.
Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. A randomized trial.
Ann Intern Med, 146 (2007), pp. 621-630
[4.]
C. Salvarani, P. Macchioni, C. Manzini, et al.
Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.
Ann Intern Med, 146 (2007), pp. 631-639
[5.]
R. Luqmani.
Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward?.
Ann Intern Med, 146 (2007), pp. 674-676
[6.]
G.S. Hoffman, P.A. Merkel, R.D. Brasington, D.J. Lenschow, P. Liang.
Anti-tumor necrosis factor therapy in patient with difficult to treat Takayasu arteritis.
Arthritis Rheum, 50 (2004), pp. 2296-2304
[7.]
A. Della Rossa, A. Tavoni, G. Merlini, C. Baldini, M. Sebastiani, M. Lombardi, et al.
Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?.
Rheumatology (Oxford), 44 (2005), pp. 1074-1075
[8.]
L. Guillevin, F. Lhote, F. Sauvaget, P. Deblois, F. Rossi, D. Levallois, et al.
Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges.
Ann Rheum Dis, 53 (1994), pp. 334-337
[9.]
J.W. Newburger, M. Takahashi, J.C. Burns, A.S. Beiser, K.J. Chung, C.E. Duffy, et al.
The treatment of Kawasaki syndrome with intravenous gamma globulin.
N Engl J Med, 315 (1986), pp. 341-347
[10.]
J.E. Weiss, B. Eberhard, D. Chowdhury, B. Gottlieb.
Infliximab as a novel therapy for refractory Kawasaki disease.
J Rheumatol, 31 (2004), pp. 808-810
[11.]
J.C. Burns, W.H. Mason, S.B. Hauger, H. Janai, J.F. Bastian, J.D. Wohrley, et al.
Infliximab treatment for refractory Kawasaki syndrome.
J Pediatr, 146 (2005), pp. 662-667
[12.]
J. Samuels, R. Spiera.
Newer therapeutic approaches to the vasculitides: Biologic Agents.
Rheum Dis Clin North Am, 32 (2006), pp. 187-200
[13.]
Wegener's Granulomatosis Etanercept Trial (WGET) Research Group.
Etanercept plus standard therapy for Wegener's granulomatosis.
N Engl J Med, 352 (2005), pp. 351-361
[14.]
U. Specks, F.C. Fervenza, T.J. McDonald, et al.
Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.
Arthritis Rheum, 44 (2001), pp. 2836-2840
[15.]
P. Eriksson.
Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
J Intern Med, 257 (2005), pp. 540-548
[16.]
K.A. Keogh, M.E. Wylam, J.H. Stone, et al.
Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.
Arthritis Rheum, 52 (2005), pp. 262-268
[17.]
O. Arbach, W.L. Gross, A. Gause.
Treatment of refractory Churg-Strauss Syndrome by TNF-alpha blockade.
Immunobiology, 206 (2002), pp. 496-501
[18.]
M. Koukoulaki, K.G. Smith, D.R. Jayne.
Rituximab in Churg-Strauss syndrome.
Ann Rheum Dis, 65 (2006), pp. 557-559
[19.]
E. Tatsis, A. Schnabel, W.L. Gross.
Interferon-alpha treatment of four patients with the Churg-Strauss syndrome.
Ann Intern Med, 129 (1998), pp. 370-374
[20.]
C. Kroegel, B. Mock, A. Reissig.
Interferons and their application in lung diseases.
Chest, 124 (2003), pp. 2406
[21.]
M.S. Genta, R.M. Genta, C. Gabay.
Systemic rheumatoid vasculitis: A review.
Semin Arthritis Rheum, 36 (2006), pp. 88-98
[22.]
J.E. Gottenberg, L. Guillevin, O. Lambotte, et al.
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Ann Rheum Dis, 64 (2005), pp. 913-920
[23.]
P. Cacoub, O. Lidove, T. Maisonobe, P. Duhaut, V. Thibault, P. Ghillani, et al.
Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Arthritis Rheum, 46 (2002), pp. 3317-3326
[24.]
P. Cacoub, D. Saadoun, N. Limal, D. Sene, O. Lidove, J.C. Piette.
Pegylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Arthritis Rheum, 52 (2005), pp. 911-915
[25.]
D. Sansonno, V. De Re, G. Lauletta, F.A. Tucci, M. Boiocchi, F. Dammacco.
Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20.
Blood, 101 (2003), pp. 3818-3826
[26.]
F. Zaja, S. De Vita, C. Mazzaro, S. Sacco, D. Damiani, G. De Marchi, et al.
Efficacy and safety of rituximab in type II mixed cryoglobulinemia.
Blood, 101 (2003), pp. 3827-3834
[27.]
I. Kötter, M. Zierhut, A. Eckstein, et al.
Human recombinant interferonalpha2a for the treatment of Behçet's disease with sight-threatening posterior or panuveitis.
Br J Ophthalmol, 87 (2003), pp. 423-431
[28.]
I. Kötter, I. Günaydin, M. Zierhut.
Nicole Stübiger. The use of interferon α in behçet disease: Review of the literature.
Semin Arthritis Rheum, 33 (2004), pp. 320-335
[29.]
E. Alpsoy, C. Durusoy, E. Yilmaz, Y. Özgürel, O. Ermis, S. Yazar, et al.
Interferon alfa-2a in the treatment of Behçet disease: A randomized placebo-controlled and double-blind study.
Arch Dermatol, 138 (2002), pp. 467-471
[30.]
B. Mushtaq, T. Saeed, R.D. Situnayake, P.I. Murray.
Adalimumab for sight-threatening uveitis in Behcet's disease.
[31.]
M. Melikoglu, I. Fresko, C. Mat, Y. Ozyazgan, F. Gogus, S. Yurdakul, et al.
Short-Term Trial of Etanercept in Behçet's Disease: A double blind, placebo controlled study.
Rheumatol, 32 (2005), pp. 98-105
[32.]
N. Pipitone, I. Olivieri, F. Cantina, G. Triolod, C. Salvarani.
New approaches in the treatment of Adamantiades-Behçet's disease.
Curr Opin Rheumatol, 18 (2006), pp. 3-9
[33.]
P.P. Sfikakis, N. Markomichelakis, E. Alpsoy, et al.
Anti-TNF therapy in the management of Behcet's disease: review and basis for recommendations.
Rheumatology, 46 (2007), pp. 736-741
[34.]
B. Haraoui, E. Keystone.
Musculoskeletal manifestations and autoimmune diseases related to new biologic agents.
Curr Opin Rheumatol, 18 (2006), pp. 96-100
[35.]
T. Jonsdottir, J. Forslid, A. Vollenhoven, et al.
Treatment with tumour necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
Ann Rheum Dis, 63 (2004), pp. 1075-1078
Copyright © 2008. Elsevier España S.L. Barcelona
Idiomas
Reumatología Clínica
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?